Page 21 - Anjali Singh

DRL to Cipla: Pharma Inc firms up plans to launch anti-obesity drugs

Push comes as patents are set to expire in March 2026

July PV dispatches flat amid high inventory, festive season to boost demand

Domestic passenger vehicle dispatches show flat growth in July, but experts remain optimistic that the festive season and monsoon will revive demand

Sun Pharma Q1 net profit falls 20% Y-o-Y; revenue rises 9%

Litigation, drug discontinuation weigh on earnings; US market remains sluggish even as India sales and Leqselvi launch boost specialty push

Iveco deal to fuel global expansion, exports for Tata Motors' CV unit

For Tata Motors, whose CV division currently earns nearly 90 per cent of its ₹75,000 crore revenue from India, the acquisition represents a strategic leap into new geographies

Tata Motors to acquire Iveco's non-defence business for €3.8 billion

The acquisition will create a €22 billion global CV giant with annual volumes of 540,000 units, expanding Tata's footprint into Europe and low-emission technology

JB Pharma Q1 profit up 14%, revenue up 9% on domestic segment gains

Domestic, CDMO and API businesses drive growth for JB Pharma in Q1FY26 as Razel crosses Rs 100 crore and ophthalmology portfolio sees 19 per cent expansion

Auto companies align dispatches with retail demand amid stock pileup

Passenger vehicle dispatches rise just 0.5% in H1 2025 as OEMs curb factory output to align with slower retail demand and elevated dealer stock levels

Cipla Q1 net profit up 10%, driven by consumer health and generics

Cipla reports a 10% increase in Q1FY26 net profit, fueled by strong performance in the generics and consumer health segments

Egg-freezing sees demand surge across cities as infertility rises

Rising infertility, delayed motherhood and increased awareness are driving demand for egg freezing across India, with clinics reporting a surge in inquiries from urban women

CDMOs gear up for peptide boom amid rising demand for weight-loss drugs

With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent expiries such as that of semaglutide in 2026

Used luxury car sales jump 30% in tier 2 cities; 80% buys now digital

According to Spinny's April-June quarter report, Audi Q3, BMW X1, and Mercedes GLA were the top luxury models sold

Dr Reddy Laboratories Q1 profit up 2%, posts best ever quarterly revenue

The company clocked its highest ever quarterly revenue at ₹8,545 crore, up by 11 per cent year-on-year (Y-o-Y) from ₹7,672 crore

EV startup MATTER launches ₹1.93 lakh Aera 5000+ e-bike, eyes IPO

Ahmedabad-based MATTER aims to disrupt the 150-200cc bike segment with its Aera 5000+, backed by global investors and planning a $200 million fundraising and public listing

Cipla buys 20% stake in iCaltech to broaden respiratory device portfolio

Cipla has acquired a 20% stake in iCaltech Innovations for Rs 5 crore, expanding its presence in the respiratory diagnostics segment with a strategic investment in medical device development

Renault Group names Stephane Deblaise as new CEO for India operations

Renault Group appoints Stephane Deblaise as the new CEO for India operations, effective September 1, 2025, as part of the company's strategy to enhance growth in the Indian market

Renault to launch all-new models with updated logo, starting with Triber

Renault India will feature its updated interlocked diamond logo on future models, beginning with the launch of the all-new Triber, as part of its ongoing brand transformation

Sun Pharma's psoriasis drug delivers positive results in arthritis trials

Sun Pharma's psoriasis drug Ilumya shows promising results in late-stage psoriatic arthritis trials, paving the way for potential regulatory filings and expansion into the immunology market.

Tyre industry to grow 7-8% in FY26, driven by replacement demand: Crisil

Crisil expects India's Rs 1 trillion tyre industry to grow 7-8% in FY26, mainly driven by replacement demand, while OEM volumes and global trade risks continue to pose challenges

CORONA Remedies acquires 7 pharma brands from Bayer India, plans expansion

CORONA Remedies deepens footprint in women's healthcare and cardiology with Bayer India portfolio acquisition, entering anti-platelet and hormone therapy segments

Ceat Q1FY26: Profit declines 27% on higher costs, revenue rises 10.5%

Ceat Q1 net profit declines 27 per cent due to IPL-linked marketing spends and higher input costs even as revenue rises 10.5 per cent on strong OEM and replacement demand